Jones Hill Capital »

Entrada Therapeutics shares owned by Jones Hill Capital

Quarter-by-quarter ownership of Entrada Therapeutics (TRDA) shares owned by Jones Hill Capital from 13F filings

Historical chart of Jones Hill Capital investment in Entrada Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Entrada Therapeutics held by Jones Hill Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Entrada Therapeutics by Jones Hill Capital

Quarter filed Position value Share count Share price at filing
2026-03-31 $4.7M 374k 12.62

More positions owned by Jones Hill Capital

BioMarin Pharmaceutical (BMRN)
Vertex Pharmaceuticals Incorporated (VRTX)
Vaxcyte (PCVX)
Nuvalent Inc-a (NUVL)
Capricor Therapeutics Com New (CAPR)
Terns Pharmaceuticals (TERN)
Bicara Therapeutics (BCAX)
Biosante Pharmaceuticals (ANIP)
Ultragenyx Pharmaceutical (RARE)
Enliven Therapeutics (ELVN)
Amylyx Pharmaceuticals (AMLX)
Argenx Se Sponsored Adr (ARGX)
Fulcrum Therapeutics (FULC)
Vir Biotechnology (VIR)
Nuvation Bio Com Cl A (NUVB)

View all positions for Jones Hill Capital

Top funds holding Entrada Therapeutics

Baker Bros. Advisors
5AM Venture Management
BlackRock
TCG Crossover Management
Vanguard Capital Management
Wellington Management Company
StepStone
Geode Capital Management
State Street Corporation
Millennium Management
Jones Hill Capital
Jacobs Levy Equity Management
Acadian Asset Management
Dimensional Fund Advisors
Northern Trust

View all funds holding Entrada Therapeutics